 |
市場調査レポート
商品コード
1455122
中枢神経系（CNS）治療薬の世界市場規模、シェア、成長分析：疾患別、薬剤クラス別、流通チャネル別 - 産業予測（2024年～2031年）Global CNS Therapeutics Market Size, Share, Growth Analysis, By Disease, By Drug Class, By Distribution Channel - Industry Forecast 2024-2031 |
||||||
| 中枢神経系（CNS）治療薬の世界市場規模、シェア、成長分析：疾患別、薬剤クラス別、流通チャネル別 - 産業予測（2024年～2031年） |
|
出版日: 2024年03月20日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
中枢神経系（CNS）治療薬の世界市場規模は、2022年に1,282億9,000万米ドルと評価され、予測期間（2024年～2031年）のCAGRは6.30%で、2023年の1,363億7,000万米ドルから2031年には2,223億3,000万米ドルに成長する見通しです。
中枢神経系（CNS）治療薬の世界市場は、ヘルスケアと医薬品セクターの中に位置し、絶え間ない進化とダイナミズムを特徴としています。神経疾患や精神疾患の治療を幅広くカバーするこの分野は、中枢神経系の複雑さに関する見識の高まりと、現在進行中の研究努力から利益を得ています。この分野の成長を促進する主な要因としては、メンタルヘルス問題に対する意識の高まりや人口の高齢化が挙げられ、中枢神経系治療薬に対する需要が拡大しています。製薬企業と研究機関の連携は、この分野の技術革新をさらに推進します。技術的・科学的進歩は中枢神経系疾患を患う人々の生活の質の向上を約束しますが、規制上のハードル、価格設定、市場競争などの課題により、業界各社は戦略的対応を迫られています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
世界の中枢神経系（CNS）治療薬市場：疾患別
- 市場概要
- 神経血管疾患
- 外傷（トラウマ）
- メンタルヘルス
- 変性疾患
- 感染症
- がん
- その他
世界の中枢神経系（CNS）治療薬市場：薬剤クラス別
- 市場概要
- 鎮痛剤
- 抗うつ薬
- 麻酔薬
- 抗パーキンソン病薬
- 抗てんかん薬
- その他
世界の中枢神経系（CNS）治療薬市場：流通チャネル別
- 市場概要
- 病院薬局
- 小売薬局
世界の中枢神経系（CNS）治療薬市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Biogen Inc.（US）
- Otsuka Pharmaceutical Co. Ltd（Japan）
- Eli Lilly and Company（US）
- Merck & Co.（US）
- AstraZeneca（UK）
- Takeda Pharmaceutical Company Limited（Japan）
- Novartis AG（Switzerland）
- Teva Pharmaceutical Industries Ltd.（Israel）
- Johnson & Johnson Private Limited（US）
- Pfizer Inc.（US）
- GlaxoSmithKline PLC（UK）
- Sanofi（France）
- AbbVie Inc.（US）
- Roche Holding AG（Switzerland）
- Bristol-Myers Squibb（US）
- Lundbeck A/S（Denmark）
- Allergan PLC（Ireland）
- Eisai Co., Ltd.（Japan）
- UCB S.A.（Belgium）
- Sunovion Pharmaceuticals Inc.（US）
Global CNS Therapeutics Market size was valued at USD 128.29 Billion in 2022 and is poised to grow from USD 136.37 Billion in 2023 to USD 222.33 Billion by 2031, at a CAGR of 6.30% during the forecast period (2024-2031).
The Global Central Nervous System (CNS) Therapeutics market, situated within the healthcare and pharmaceutical sector, is characterized by constant evolution and dynamism. Covering a broad spectrum of treatments for neurological and psychiatric disorders, this sector benefits from increasing insights into the intricacies of the central nervous system and ongoing research endeavors. Key factors driving its growth include heightened awareness of mental health issues and an aging population, expanding the demand for CNS therapeutics. Collaboration between pharmaceutical entities and research institutions further propels innovation in the field. While technological and scientific progress promises enhanced quality of life for those afflicted by CNS disorders, challenges such as regulatory hurdles, pricing dynamics, and market competition necessitate strategic responses from industry players.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global CNS Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global CNS Therapeutics Market Segmental Analysis
The global CNS therapeutics market is segmented on the basis of Disease, Disease type, distribution channel, and region. Based on disease the market is segmented as Neurovascular Diseases, Trauma, Mental Health, Degenerative Disease, Infectious Diseases, Cancer, and Others. On the basis of disease type the market is segmented as Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Other Drug Classes. Based on distribution channel, it is segregated into Hospitals Pharmacies, Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global CNS Therapeutics Market
As the global population ages, there is a noticeable increase in the occurrence of neurological disorders such as Alzheimer's and Parkinson's disease. This shift in demographics escalates the need for treatments and therapies targeting the central nervous system (CNS), as the elderly are particularly vulnerable to these ailments.
Restraints in the Global CNS Therapeutics Market
The process of creating drugs and treatments for neurological and psychiatric disorders entails navigating through thorough clinical trials and regulatory obstacles. The stringent examination conducted by regulatory bodies often results in delays and heightened expenses in introducing new therapies to the market, impeding both innovation and the prompt availability of effective treatments for patients.
Market Trends of the Global CNS Therapeutics Market
Advancements in genetics and neuroimaging have facilitated a comprehensive comprehension of diverse individual characteristics in central nervous system (CNS) disorders. This progression entails customizing treatments according to a patient's distinct genetic composition, neurobiological traits, and therapeutic responsiveness, thereby enhancing the precision and efficacy of interventions while reducing negative repercussions. Personalized methodologies hold the promise of transforming the treatment paradigm for ailments such as Alzheimer's, depression, and schizophrenia, presenting a hopeful trajectory for enhancing patient outcomes within the CNS therapeutics sector.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global CNS (Central Nervous System) Therapeutics Market by Disease
- Market Overview
- Neurovascular Diseases
- Trauma
- Mental Health
- Degenerative Disease
- Infectious Diseases
- Cancer
- and Others
Global CNS (Central Nervous System) Therapeutics Market by Drug Class
- Market Overview
- Analgesics
- Antidepressants
- Anesthetics
- Anti-Parkinson Drugs
- Anti-Epileptics
- and Other Drug Classes
Global CNS (Central Nervous System) Therapeutics Market by Distribution Channel
- Market Overview
- Hospitals Pharmacies
- Retail Pharmacies
Global CNS (Central Nervous System) Therapeutics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Otsuka Pharmaceutical Co. Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Private Limited (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sunovion Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
